Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Human Papillomavirus Vaccines
Researchers from National Institute of Infectious Disease publish findings in human papillomavirus vaccines
May 13th, 2008
Scientists discuss in 'Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes' new findings in human papillomavirus. According to recent research from Tokyo, Japan, "Infection with human papillomavirus 16 (HPV16), which is one of the 15 types of HPV causally associated with cervical cancer and accounts for 50% of the cases, can be prevented in a type-specific manner by an HPV16 virus-like particle (VLP) vaccine comprised of particles of the L1 protein alone. We attempted to modify the VLP vaccine by inserting the HPV16 L2-peptides including cross-neutralization epitopes into the L1 polypeptide." "The chimeric L1 had,...
Source: Cancer Weekly (2008-05-13)
|
